Safety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia and Canada

[1]  A. Garg,et al.  Kidney function and the comparative effectiveness and safety of direct oral anticoagulants versus warfarin in adults with atrial fibrillation: a multicenter observational study. , 2022, European heart journal. Quality of care & clinical outcomes.

[2]  K. Bleicher,et al.  Cohort Profile Update: The 45 and Up Study , 2022, International journal of epidemiology.

[3]  Jonathan W. Inselman,et al.  Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients With Atrial Fibrillation , 2020, Circulation. Cardiovascular quality and outcomes.

[4]  N. Roetker,et al.  Direct-Acting Oral Anticoagulants Versus Warfarin in Medicare Patients With Chronic Kidney Disease and Atrial Fibrillation , 2020, Stroke.

[5]  Bette C Liu,et al.  EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (the EXTEND45 Study): Protocol for an Australian Linked Cohort Study , 2020, JMIR research protocols.

[6]  A. Meinecke,et al.  Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis. , 2019, The American journal of medicine.

[7]  F. McAlister,et al.  Sensitivity, specificity, positive and negative predictive values of identifying atrial fibrillation using administrative data: a systematic review and meta-analysis , 2019, Clinical epidemiology.

[8]  David W. Johnson,et al.  Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease , 2019, Annals of Internal Medicine.

[9]  J. Coresh,et al.  Risks and Benefits of Direct Oral Anticoagulants across the Spectrum of GFR among Incident and Prevalent Patients with Atrial Fibrillation. , 2018, Clinical journal of the American Society of Nephrology : CJASN.

[10]  J. Brophy,et al.  Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study , 2018, BMJ Open.

[11]  P. Noseworthy,et al.  Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. , 2017, Journal of the American College of Cardiology.

[12]  A. Garg,et al.  Incident Atrial Fibrillation and the Risk of Congestive Heart Failure, Myocardial Infarction, End-Stage Kidney Disease, and Mortality Among Patients With a Decreased Estimated GFR. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  J. Schein,et al.  Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence , 2017, Current medical research and opinion.

[14]  A. Webster,et al.  Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  A. Go,et al.  Incident Atrial Fibrillation and Risk of Death in Adults With Chronic Kidney Disease , 2014, Journal of the American Heart Association.

[16]  M. Hori,et al.  Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[17]  James Floyd,et al.  A systematic review of validated methods for identifying atrial fibrillation using administrative data , 2012, Pharmacoepidemiology and drug safety.

[18]  D. Singer,et al.  Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. , 2011, European heart journal.

[19]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[20]  P. Austin.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.

[21]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[22]  H. Bruck,et al.  Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. , 2010, British journal of clinical pharmacology.

[23]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[24]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[25]  D. Singer,et al.  Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study , 2009, Circulation.

[26]  Peter C Austin,et al.  A comparison of propensity score methods: a case‐study estimating the effectiveness of post‐AMI statin use , 2006, Statistics in medicine.

[27]  M. Hill,et al.  Coding of Stroke and Stroke Risk Factors Using International Classification of Diseases, Revisions 9 and 10 , 2005, Stroke.

[28]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[29]  G. Breithardt,et al.  Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease. , 2015, Kidney international.

[30]  J. Stockman,et al.  A New Equation to Estimate Glomerular Filtration Rate , 2011 .

[31]  A. Niessner.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[32]  A. Forster,et al.  Accuracy of coding for possible warfarin complications in hospital discharge abstracts. , 2006, Thrombosis research.

[33]  J. Knight,et al.  coding in , 2022 .